The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
FDA -- Integrated Pathogen Reduction Technologies for whole blood and blood components for transfusion (R01) Clinical Trial Not Allowed
The purpose of this Request for Application (RFA) is to support the Center of Biologics Evaluation and Research in identifying pathogen inactivation technology that could be applied to whole blood at the point of collection or just after, followed by separation of that blood into components (red blood cells, platelets, and plasma), potentially reducing or eliminating donor deferral and/or testing requirements. This project involving a moderately-sized pilot program would assess the feasibility of the widespread introduction of pathogen inactivation of whole blood that is collected. The request would cover completion of necessary preparatory basic laboratory-based research work, purchase of the necessary equipment, and contracting for the blood banking services required for the demonstration of the feasibility of this approach.
Application Due Date(s): April 22, 2020
RFA-FD-20-027 Expiration Date April 23, 2020
Application budgets need to reflect the actual needs of the proposed project and should not exceed the following in total costs (direct and indirect):
YR 01: $1,600,000
YR 02: $1,600,000